Geovana S F Leite

Geovana S F Leite

Auto-generated profile, based on publicly available information

Geovana S F Leite

Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2026 in Blood Advances
Verified
Journal Article
Open access
HBHelena Batatinha
Helena Batatinha
AVAngella M. Valenzuela
Angella M. Valenzuela
DFDimitrios Filioglou
Dimitrios Filioglou
PVPhelipe Varela
Phelipe Varela
GLGeovana Leite
Geovana Leite
EKEmmanuel Katsanis
Emmanuel Katsanis
Short-term activation of natural killer (NK) cells with interleukin-12 (IL-12), IL-15, and IL-18 (IL-12/15/18) gives rise to cytokine-induced memory-like (CIML) NK cells after adoptive transfer, which exhibit enhanced antitumor activity, proliferation, and persistence. Clinical trials in high-risk leukemia have shown encouraging results, yet significant challenges remain, particularly the limited durability of cytotoxicity and the failure to achieve sustained remission. We recently demonstrated that acute exercise induces a threefold to fourfold increase in circulating NK cells enriched for gene programs and surface proteins linked to antitumor activity. Here, we tested whether exercise-mobilized NK cells could improve the function of IL-12/15/18–activated NK (aNK) cells in vitro and CIML NK cells in vivo. Eighteen healthy donors performed 20 minutes of graded cycling up to 80% maximal oxygen uptake, with blood collected at rest and during exercise. NK cells purified from rest and exercise (NK-X) were cultured overnight with IL-15 (NK or NK-X) or IL-12/15/18 (aNK or aNK-X). End points included in vitro cytotoxicity and tumor control in leukemia-bearing xenogeneic mice. aNK-X cells exhibited stronger cytotoxicity against 2 myeloid leukemia cell lines than aNK cells from the same donors, accompanied by increased interferon gamma production, enhanced degranulation, and an enriched phenotype (higher NKG2A-/NKG2D+, CD57+, CD16+). Notably, NK-Xs displayed greater cytotoxic activity than NKs and were comparable with aNK cells, although aNK-X cells outperformed both. In mice, CIML NK-X cells combined with exercise-mobilized donor lymphocyte infusion (DLI-X) prolonged engraftment, delayed tumor progression, and extended survival relative to CIML NK cells combined with standard DLI. These findings demonstrate that exercise-induced NK cell mobilization combined with cytokine preactivation yields an adoptive cell therapy product with superior antileukemic activity. This trial was registered at www.ClinicalTrials.gov as NCT06643221.

12 June 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
GLGeovana S F Leite
Geovana S F Leite
JSJohn Sullivan
John Sullivan
DFDimitrios Filioglou
Dimitrios Filioglou
MKMatina Kounelis
Matina Kounelis
HBHelena Batatinha
Helena Batatinha
Emmanuel KatsanisEmmanuel Katsanis
Emmanuel Katsanis
Background: Relapse and graft-versus-host disease (GvHD) remain primary causes of treatment failure in patients with B-cell acute lymphoblastic leukemia (B-ALL) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While abatacept (ABATA) effectively mitigates GvHD via CD28-costimulation blockade, there is significant concern that it concurrently diminishes graft-versus-leukemia (GvL) effects, potentially leading to higher relapse rates. We investigated whether blinatumomab (BLINA) retains antileukemic efficacy in the presence of ABATA using in vitro assays and humanized NOD.Cg-Prkdc scid Il2rg tm1Wjl Tg(IL15)1Sz/SzJ (NSG-IL15) and NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mouse models. Methods: In vitro and ex vivo flow cytometry-based cytotoxicity, degranulation (CD107a), cytokine production (interferon (IFN)-γ), and activation-marker (CD25, CD69, CD137, OX40) assays were performed using healthy donor peripheral blood mononuclear cells (PBMCs) (pretreated±ABATA) against leukemia or lymphoma cell lines (RS4;11, NALM-6, and JEKO-1) in the presence or not of BLINA. In vivo human PBMC-reconstituted NSG-IL-15 mice bearing RS4;11 B-ALL xenografts were treated with vehicle, monotherapy (BLINA or ABATA), or combination therapy. Leukemia burden and immune reconstitution were assessed through week 4; GvHD scores and overall survival were monitored longitudinally. Results: ABATA did not impair BLINA-mediated cytotoxicity across multiple effector-to-target ratios against any of the cell lines, nor did it reduce BLINA-induced degranulation, IFN-γ production, or activation marker expression. In vivo, BLINA monotherapy significantly reduced leukemia burden, but resulted in early mortality due to severe GvHD. Conversely, ABATA markedly reduced GvHD severity. The combination of BLINA and ABATA preserved potent antileukemic efficacy while significantly extending median survival by 35 days compared with tumor controls (p<0.0001). Although ABATA attenuated T-cell expansion and differentiation, BLINA-driven cytotoxic function was maintained, even after prolonged in vivo exposure to cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA-4-Ig). Conclusion: These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.

1 January 2026 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
EFElias De França
Elias De França
CMCamila G. Marques
Camila G. Marques
GLGeovana S. Fogaça Leite
Geovana S. Fogaça Leite
AMAna Carolina O. Magalhães
Ana Carolina O. Magalhães
ECErico Caperuto
Erico Caperuto
RTRonaldo Thomatieli-Santos
Ronaldo Thomatieli-Santos
This study aims to elucidate potential connections between various health-related factors and reported adverse effects (AEs) following COVID-19 vaccination. Using the “snowball sampling” method, we collected data from 301 Brazilians participants, both sexes, who underwent COVID-19 vaccination during SARS-CoV-2 pandemic. We also collected data from general health status, vaccine type received, sleep quality, physical activity levels, dietary habits, alcohol consumption, history of COVID-19 infection, and the use of chronic medications. Employing a decision tree regression (DTR) model, we sought to unravel intricate associations between lifestyle, health profile, and AEs attributed to COVID-19 vaccines. Our DTR analysis revealed that AEs tended to be lower in older individuals, with sleep quality further influencing this decrease (all P≤0.02). Intriguingly, individuals with suboptimal sleep efficiency were also users of medication, and notably, medication usage appeared to mitigate AEs in this subgroup (all P≤0.01). Here, we demonstrate that the DTR is a valuable model for investigating the AEs related to COVID-19 vaccines. In summary, our findings underscore the impact of age, sleep efficiency, and medication use for non-COVID-19-related conditions in explaining the observed AEs following COVID-19 vaccination.